M

Marker Therapeutics
D

MRKR

2.33000
USD
0.16
(7.37%)
مغلق
حجم التداول
1,379
الربح لكل سهم
-4
العائد الربحي
-
P/E
-2
حجم السوق
24,947,997
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    AXON
    6.09
    (1.00%)
    613.29 USD
    C
    CRIS
    0.17000
    (5.21%)
    3.43000 USD
    G
    GH
    1.440
    (3.05%)
    48.620 USD
    I
    IONS
    1.920
    (5.91%)
    34.430 USD
    M
    MGTX
    0.02000
    (0.33%)
    6.06500 USD
    V
    VYGR
    0.09000
    (1.65%)
    5.54000 USD
    X
    XBIT
    -0.09300
    (-2.45%)
    3.69700 USD
    R
    RDUS
    -0.185
    (-1.42%)
    12.850 USD
    المزيد
الأخبار
المقالات

العنوان: Marker Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.